<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2304">
  <stage>Registered</stage>
  <submitdate>25/03/2009</submitdate>
  <approvaldate>25/03/2009</approvaldate>
  <nctid>NCT00870051</nctid>
  <trial_identification>
    <studytitle>Endurant Stent Graft Natural Selection Global Postmarket Registry</studytitle>
    <scientifictitle>Endurant Stent Graft Natural Selection Global Postmarket Registry</scientifictitle>
    <utrn />
    <trialacronym>ENGAGE</trialacronym>
    <secondaryid>P#888</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Aortic Aneurysm, Abdominal</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Endurant Stent Graft

AAA patients - Subjects diagnosed with an AAA who are considered candidates for endovascular repair with Endurant Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this registry


Treatment: devices: Endurant Stent Graft
Endurant Stent Graft implantation

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment success Treatment Success</outcome>
      <timepoint>10 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Stent Graft Migration</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stent Graft Patency</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stent Graft Endoleaks</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary procedures to correct Type I and III endoleaks</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary endovascular procedure</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Device Effects</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Technical Observations</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Aneurysm-related mortality</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All-cause mortality</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>MAE</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health Related Quality of Life Scores</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stent Graft Stenosis - Stent Graft stenosis is considered a reduction in the diameter of the stent graft lumen as compared to the reference. SG stenosis will be assessed by imaging as CT with contrast, Ultrasound, etc.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AAA Diameter Increase</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age =18 years or minimum age as required by local regulations

          -  Indication for elective surgical repair of AAA with an endovascular stent graft in
             accordance with the applicable guidelines on endovascular interventions and the
             Instructions for Use of the Endurant Stent Graft System

          -  Signed consent form ("Patient informed consent Form" or "Patient Data Release
             Authorization Form"). The subject or legal representative has been informed of the
             nature of the trial and has consented to participate and authorized the collection and
             release of his medical information

          -  Intention to electively implant the ENDURANT Stent Graft System

          -  Ability and willingness to comply with the CIP.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  High probability of non-adherence to physician's follow-up requirements

          -  Current participation in a concurrent trial which may confound study results</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Queen Elizabeth Hospital - Adelaide</hospital>
    <postcode>SA 5011 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Endovascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of ENGAGE is to prospectively collect global 'real world' data on the Endurant
      Stent Graft System from AAA subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00870051</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Vicente Riambau, Prof.</name>
      <address>Hospital Clinic of Barcelona</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>